A SMYD3 inhibitor named BCI-121 (Figure 1) with anti-proliferative effects on tumor cell lines including prostate cancer models has been described, and its activity was linked to SMYD3 levels [116]. The gene discussed is SMYD3; the disease is neoplasm.